Alpha 2.0
Login Register
» Authors » L Machet

L Machet

Explore the profile of L Machet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 180
Citations 785
Followers 0
Related Specialties
Dermatology
Infectious Diseases
General Medicine
Top 10 Co-Authors
L Vaillant
G Lorette
M C Machet
A de Muret
L Martin
A Maruani
V Jan
E Esteve
M Beylot-Barry
A Callens
Published In
Ann Dermatol Venereol
Br J Dermatol
Acta Derm Venereol
Contact Dermatitis
Dermatology
Affiliations
Soon will be listed here.
Recent Articles
1.
Correlation of serum level of squamous cell carcinoma antigen with severity of cutaneous psoriasis, assessed using the simplified psoriasis index
Henry D, Alkhars A, Samimi M, Dufour D, Machet L
Ann Dermatol Venereol . 2024 Feb; 151(1):103246. PMID: 38422600
Background: Squamous cell carcinoma antigen (SCCA) is a biomarker of disease progression in squamous cell carcinoma but also contributes to the pathogenesis of psoriasis. Eight previous studies have shown a...
2.
Sudden appearance of pruritic eruption with comet sign due to Pyemotes sp
Albert M, Finon A, Machet L
Br J Dermatol . 2020 May; 183(4):e91. PMID: 32399981
No abstract available.
3.
A previously unreported frameshift ATP2C1 mutation in a generalized Hailey-Hailey disease
Leducq S, Duchatelet S, Zaragoza J, Ventejou S, de Muret A, Eymieux S, et al.
J Eur Acad Dermatol Venereol . 2019 Oct; 34(3):e118-e120. PMID: 31660662
No abstract available.
4.
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect
Chen D, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al.
Br J Dermatol . 2019 Sep; 182(5):1111-1119. PMID: 31487383
Background: Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives:...
5.
[Phototesting in France: A survey by French Society for Photodermatology]
Moreau A, Avenel-Audran M, Adamski H, Aubin F, Beani J, Bedane C, et al.
Ann Dermatol Venereol . 2019 May; 146(8-9):577-581. PMID: 31101384
No abstract available.
6.
Skin cancers in patients of skin phototype V or VI with xeroderma pigmentosum type C (XP-C): A retrospective study
Ventejou S, Bagny K, Waldmeyer J, Cartault F, Machet L, Osdoit S
Ann Dermatol Venereol . 2019 Mar; 146(3):192-203. PMID: 30853323
Background: Xeroderma pigmentosum (XP) is a rare genetic disease comprising 7 subgroups, A to G, all of which are associated with early onset of several forms of skin cancer. Our...
7.
[Paraneoplastic pemphigus: Retrospective study of a case series]
Fournet M, Roblot P, P Levillain , Guillet G, Machet L, Misery L
Ann Dermatol Venereol . 2018 Aug; 145(10):564-571. PMID: 30126641
Context: Paraneoplastic pemphigus (PNP) is a rare condition associated with poor prognosis. It associates polymorphic mucocutaneous manifestations with neoplasia. Diagnosis is difficult because of the various clinical and histological features...
8.
Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors
Machet L, Zaragoza J, Finon A, Garnier M, Maillard H, Caille A
Br J Dermatol . 2018 Apr; 179(1):224. PMID: 29660775
No abstract available.
9.
A new nonsense mutation in the POGLUT1 gene in two sisters with Dowling-Degos disease
Duchatelet S, Clerc H, Machet L, Gaboriaud P, Miskinyte S, Kervarrec T, et al.
J Eur Acad Dermatol Venereol . 2018 Mar; 32(12):e440-e442. PMID: 29569780
No abstract available.
10.
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma
Marchand A, Tallet A, Collin C, Cormier B, Venel Y, Miquelestorena-Standley E, et al.
Br J Dermatol . 2018 Mar; 179(2):528-529. PMID: 29494756
No abstract available.